首页 / 院系成果 / 成果详情页

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study 期刊论文

编号：

f5f44d5c-f00f-4118-b0d2-39f07988b1d6
作者：

Leng, Yun(冷芸)#^[1]Hou, Jian^[2];Jin, Jie^[3];Zhang, Mei^[4];Ke, Xiaoyan^[5,6];Jiang, Bin^[7];Pan, Ling^[8];Yang, Linhua^[9];Zhou, Fang^[10];Wang, Jianmin^[11];Wang, Zhao^[12];Liu, Li^[13];Li, Wei(李薇)^[14]Shen, Zhixiang^[15];Qiu, Lugui^[16,17,18];Chang, Naibai^[19];Li, Jianyong^[20];Liu, Jing^[21];Pang, Hongyan^[22];Meng, Haitao^[3];Wei, Peng^[22];Jiang, Hua^[2];Liu, Yan^[5,6];Zheng, Xiangjun^[22];Yang, Shifang^[22];Chen, Wenming(陈文明)*^[1]
语种：

英文
期刊：

CANCER CHEMOTHERAPY AND PHARMACOLOGY ISSN：0344-5704 2017 年 79 卷 6 期 (1141 - 1149) ; JUN
收录：
关键词：

Recombinant human circularly permuted TRAIL Multiple myeloma Thalidomide Dexamethasone Phase 2 clinical trials
摘要：

Purpose Circularly permuted TRAIL (CPT) has exhibited promising efficacy as a mono-therapy or in combination with thalidomide for patients with multiple myeloma (MM). In this phase 2 study, the safety and efficacy of CPT in combination with thalidomide and dexamethasone (CPT+TD) was evaluated in patients with pretreated relapsed/refractory MM (RRMM).
Methods Patients who received at least two previous therapies for MM were randomly assigned at a 2: 1 ratio to receive treatment with CPT + TD or thalidomide and dexamethasone (TD). The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), duration of response (DOR) and safety.
Results Overall, 47 patients were assigned to the CPT + TD group, and 24 patients were recruited to the TD group. The ORR in the CPT + TD group was 38.3 vs. 25.0% in the TD group. The median PFS time was 6.7 months for the CPT + TD group and 3.1 months for the TD group. The median DORs for the CPT + TD and TD groups were 7.1 and 3.2 months, respectively. Most of the adverse effects (AEs) were grade 1 or 2. Serious AEs were reported in 19.7% of the patients. No treatment-related deaths were reported.
Conclusion CPT plus TD could serve as a new therapeutic strategy for patients with RRMM.A randomized, doubleblind, placebo-controlled confirmatory study is currently under way.
推荐引用方式
GB/T 7714：

Leng Yun,Hou Jian,Jin Jie, et al. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study [J].CANCER CHEMOTHERAPY AND PHARMACOLOGY,2017,79(6):1141-1149.
APA：

Leng Yun,Hou Jian,Jin Jie,Zhang Mei,&Chen Wenming.(2017).Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study .CANCER CHEMOTHERAPY AND PHARMACOLOGY,79(6):1141-1149.
MLA：

Leng Yun, et al. "Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study" .CANCER CHEMOTHERAPY AND PHARMACOLOGY 79,6(2017):1141-1149.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：48  下载次数：0

分享到：

浏览次数：48

下载次数：0

打印次数：0